Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

NEW YORK - Neurogene Inc. (NASDAQ:NGNE), a clinical-stage biotechnology company currently trading at $14.95 per share, has received written agreement from the U.S. Food and Drug Administration on key ...

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first ...